KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Work In Process (2018 - 2025)

Historic Work In Process for Rigel Pharmaceuticals (RIGL) over the last 8 years, with Q3 2025 value amounting to $5.5 million.

  • Rigel Pharmaceuticals' Work In Process rose 20298.18% to $5.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.5 million, marking a year-over-year increase of 20298.18%. This contributed to the annual value of $1.2 million for FY2024, which is 3464.82% down from last year.
  • As of Q3 2025, Rigel Pharmaceuticals' Work In Process stood at $5.5 million, which was up 20298.18% from $2.0 million recorded in Q2 2025.
  • Rigel Pharmaceuticals' 5-year Work In Process high stood at $6.0 million for Q2 2024, and its period low was $162000.0 during Q4 2021.
  • Over the past 5 years, Rigel Pharmaceuticals' median Work In Process value was $1.5 million (recorded in 2022), while the average stood at $2.0 million.
  • In the last 5 years, Rigel Pharmaceuticals' Work In Process crashed by 8637.51% in 2021 and then soared by 154135.8% in 2022.
  • Over the past 5 years, Rigel Pharmaceuticals' Work In Process (Quarter) stood at $162000.0 in 2021, then surged by 1541.36% to $2.7 million in 2022, then dropped by 29.45% to $1.9 million in 2023, then tumbled by 34.65% to $1.2 million in 2024, then skyrocketed by 347.55% to $5.5 million in 2025.
  • Its Work In Process stands at $5.5 million for Q3 2025, versus $2.0 million for Q2 2025 and $1.1 million for Q1 2025.